International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(14), С. 11380 - 11380
Опубликована: Июль 12, 2023
Atopic
dermatitis
represents
a
complex
and
multidimensional
interaction
that
potential
fields
of
preventive
therapeutic
management.
In
addition
to
the
treatment
armamentarium
available
for
atopic
dermatitis,
novel
drugs
targeting
significant
molecular
pathways
in
biologics
small
molecules
are
also
being
developed
given
condition’s
pathophysiology.
While
most
patients
expecting
better
efficacy
long-term
control,
response
these
would
still
depend
on
numerous
factors
such
as
genotype,
diverse
environmental
triggers
microbiome-derived
signals,
and,
importantly,
dynamic
immune
responses.
This
review
article
highlights
challenges
recently
pharmacological
agents
based
pathogenesis
this
condition,
creating
specific
approach
toward
more
personalized
medicine.
Journal of Allergy and Clinical Immunology,
Год журнала:
2021,
Номер
149(4), С. 1318 - 1328
Опубликована: Дек. 1, 2021
Janus
kinase
(JAK)
inhibitors
have
shown
encouraging
results
in
the
treatment
of
alopecia
areata
(AA),
an
autoimmune
form
hair
loss,
small,
uncontrolled
studies
and
case
reports.We
conducted
a
biopsy
substudy
during
randomized,
double-blind,
placebo-controlled
first
24
weeks
phase
2a
clinical
trial
that
evaluated
efficacy
safety
ritlecitinib,
inhibitor
JAK3
tyrosine
expressed
hepatocellular
carcinoma
(TEC)
family,
brepocitinib,
2
(TYK2)/JAK1
AA.Change
biomarkers
lesional
scalp
samples
between
baseline
12
was
exploratory
end
point,
46
patients
participated
from
ritlecitinib
(n
=
18),
brepocitinib
16),
placebo
12)
groups.
Correlations
with
regrowth,
measured
using
Severity
Alopecia
Tool
(SALT)
score,
were
also
evaluated.NCT02974868.At
week
24,
both
demonstrated
improvement
exceeding
100%
transcriptome
toward
nonlesional
profile.
At
12,
improvements
tissue
greater
than
ritlecitinib;
however,
at
ritlecitinib.For
SALT
scores
positively
associated
expression
TH1
markers
negatively
keratins.
Larger,
long-term
trials
are
warranted.
International Journal of Molecular Sciences,
Год журнала:
2021,
Номер
22(19), С. 10381 - 10381
Опубликована: Сен. 26, 2021
Atopic
dermatitis
(AD)
is
the
most
common
chronic
inflammatory
skin
disease
and
significantly
impacts
patients’
lives,
particularly
in
its
severe
forms.
AD
clinical
presentation
varies
over
course
of
disease,
throughout
different
age
groups,
across
ethnicities.
characterized
by
a
spectrum
phenotypes
as
well
endotypes.
Starting
from
current
description
pathogenesis,
this
review
explores
rationale
approved
therapies
emollients
to
biologicals
introduces
novel
promising
drugs.
Journal of Allergy and Clinical Immunology,
Год журнала:
2022,
Номер
150(3), С. 690 - 700
Опубликована: Март 1, 2022
BackgroundAtopic
dermatitis
is
a
chronic
inflammatory
skin
disease
with
persistent
and
severe
itch
among
its
hallmark
features.
Significant
increases
in
type
2
cytokines
(ie,
IL-4,
IL-13,
IL-31)
have
been
documented
acute
atopic
lesions
lead
to
multifaceted
downstream
effects,
including
inflammation,
epidermal
barrier
dysfunction,
itch.ObjectiveThe
primary
objective
of
preclinical
studies
reported
here
was
test
direct
effects
IL-13
an
anti–IL-13
mAb,
lebrikizumab,
human
dorsal
root
ganglion
model
amplification,
neuronal
excitability,
transcriptional
targets.MethodsNeuroactive
were
assessed
via
live
cell
calcium
imaging,
electric
field
stimulation,
RNA
sequencing
ganglia
stimulated
alone
or
combination
lebrikizumab.ResultsThese
findings
suggest
that
plays
enhancer
role
multiple
neuroactive
pathways
as
well
provide
key
insights
into
the
mechanistic
basis
for
lebrikizumab's
anti-itch
effects.ConclusionIL-13
potent
responses
different
stimuli,
consistent
neuroimmune
axis
contributing
itch–associated
disease,
blockade
this
cytokine
pathway
may
therapeutic
approach.
Atopic
itch.
The
targets.
Neuroactive
lebrikizumab.
These
effects.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(14), С. 11380 - 11380
Опубликована: Июль 12, 2023
Atopic
dermatitis
represents
a
complex
and
multidimensional
interaction
that
potential
fields
of
preventive
therapeutic
management.
In
addition
to
the
treatment
armamentarium
available
for
atopic
dermatitis,
novel
drugs
targeting
significant
molecular
pathways
in
biologics
small
molecules
are
also
being
developed
given
condition’s
pathophysiology.
While
most
patients
expecting
better
efficacy
long-term
control,
response
these
would
still
depend
on
numerous
factors
such
as
genotype,
diverse
environmental
triggers
microbiome-derived
signals,
and,
importantly,
dynamic
immune
responses.
This
review
article
highlights
challenges
recently
pharmacological
agents
based
pathogenesis
this
condition,
creating
specific
approach
toward
more
personalized
medicine.
